[Edaily Reporter KIM JI-WAN ] As Moderna and Merck’s personalized mRNA cancer vaccines have yielded positive initial results in Phase 3 clinical trials, the technological capabilities of NeoGenLogic—a subsidiary of SCL Science(246960) that is developing AI-based personalized cancer vaccines in South Korea—are once again drawing attention.

According to foreign media reports on the 19th (local time), the personalized mRNA cancer vaccine currently being jointly developed by Moderna and Merck demonstrated a statistically significant extension in progression-free survival compared to the Keytruda monotherapy group in a Phase 3 clinical trial involving patients with high-risk melanoma.

These results are seen as significantly increasing the commercial viability of personalized cancer vaccines, which analyze mutations occurring in each patient’s tumor to identify neoantigens optimized for the individual and, based on this, induce the immune system to attack cancer cells.

As global big pharma companies accelerate the development of personalized cancer vaccines, attention is also turning to NeoGenLogic, which possesses a next-generation neoantigen discovery platform.

NeoGenLogic possesses “DeepNeo,” an AI-based cancer vaccine design platform jointly developed with Professor Choi Jeong-kyun’s research team at KAIST’s Department of Bio and Brain Engineering, as well as “DeepDependency,” a single-cell big data platform.

In particular, DeepNeo is distinguished by its ability to simultaneously analyze and predict not only T-cell but also B-cell immune responses—a capability that sets it apart from the cancer vaccine technologies of existing global pharmaceutical companies.

Conventional personalized cancer vaccine development has primarily focused on identifying neoantigens capable of inducing T-cell responses that directly attack cancer cells. In contrast, NeoGenLogic has developed the world’s first algorithm to quantitatively predict B-cell responsiveness to neoantigens, thereby securing technology to screen for candidate compounds capable of simultaneously stimulating both the T-cell and B-cell immune systems.

It has been confirmed that stimulating both the T-cell and B-cell immune systems simultaneously increases the probability of inducing an immune response by more than 4.7 times compared to conventional methods. The findings of this research were published in the international academic journal *Science Advances*.

Based on this technology, NeogenLogic has secured patents in South Korea, Japan, and China and is expanding its global patent network to major markets such as the United States and Europe.

The company is accelerating the development of personalized cancer vaccine candidates using DeepNeo and is proceeding with its development schedule with the goal of submitting an Investigational New Drug (IND) application by 2027.

An SCL Science official stated, “The success of Moderna and Merck’s Phase 3 clinical trials is a decisive milestone demonstrating that personalized cancer vaccines have entered a realistic stage of commercialization,” adding, “Based on NeoGenLogic’s unique integrated AI analysis technology for T and B cells, we are proceeding without delay toward our goal of submitting an Investigational New Drug (IND) application in 2027, and we plan to hold a briefing in September to provide detailed information on the exact timeline.”